Vinva Investment Management Ltd Has $642,000 Position in Exelixis, Inc. $EXEL

Vinva Investment Management Ltd decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 29.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,572 shares of the biotechnology company’s stock after selling 5,986 shares during the quarter. Vinva Investment Management Ltd’s holdings in Exelixis were worth $642,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Avantax Advisory Services Inc. acquired a new position in shares of Exelixis during the first quarter valued at $551,000. Cetera Investment Advisers raised its holdings in Exelixis by 1.6% during the 1st quarter. Cetera Investment Advisers now owns 118,599 shares of the biotechnology company’s stock worth $4,379,000 after purchasing an additional 1,925 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Exelixis by 3.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,913 shares of the biotechnology company’s stock valued at $2,434,000 after purchasing an additional 2,466 shares during the period. LPL Financial LLC boosted its stake in shares of Exelixis by 74.5% in the 1st quarter. LPL Financial LLC now owns 187,097 shares of the biotechnology company’s stock valued at $6,908,000 after purchasing an additional 79,885 shares during the last quarter. Finally, Natixis Advisors LLC grew its position in shares of Exelixis by 14.9% during the 1st quarter. Natixis Advisors LLC now owns 69,922 shares of the biotechnology company’s stock worth $2,582,000 after buying an additional 9,072 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 28,043 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the sale, the executive vice president owned 374,029 shares of the company’s stock, valued at $15,926,154.82. The trade was a 6.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary C. Beckerle sold 24,622 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the transaction, the director directly owned 21,380 shares of the company’s stock, valued at approximately $896,463.40. This trade represents a 53.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 245,235 shares of company stock worth $10,490,600 in the last 90 days. 2.82% of the stock is owned by corporate insiders.

Exelixis Stock Down 0.2%

Shares of NASDAQ:EXEL opened at $44.12 on Friday. The firm has a market cap of $11.83 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 0.79 and a beta of 0.32. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62. The company’s fifty day simple moving average is $40.24 and its 200 day simple moving average is $40.90.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. Research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on EXEL. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $45.00 target price on shares of Exelixis in a report on Tuesday, October 21st. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. HC Wainwright increased their target price on Exelixis from $46.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Cowen restated a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. Finally, TD Cowen increased their price target on shares of Exelixis from $44.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.45.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.